In our study, we demonstrated that ML323 [19,24], a specific USP1 inhibitor, increases the susceptibility of SCLC cells to NK cell-mediated cytotoxicity in vitro and inhibits SCLC growth in vivo. Here, USP1 is linked to small cell lung carcinoma.